The first human study using gene transfer to treat erectile dysfunction (ED) shows promising results and suggests the potential for using the technology to treat overactive bladder, irritable bowel syndrome and asthma, according to the researchers.
There is as much as a four- to five-fold increased relative risk for late thrombosis, or blood clot formation, in patients with drug-eluting stents compared to those with bare-metal stents, according to a Cleveland Clinic-led meta-analysis appearing in the December issue of the American Journal of Medicine. This is the first published analysis of its kind.
Researchers at Harvard Medical School’s Brigham and Women’s Hospital compared the effects of a variety of immunosuppressive agents on cardiovascular events in a large sample of RA patients.
The scientific evidence is strong enough to justify using folic acid as a cheap and simple way of reducing heart disease and strokes, say researchers in this week?s BMJ.
Being exposed to high levels of nutrition before birth can influence the development of networks within the brain that regulate appetite to permanently set a pattern of appetite for life, according to researchers from the University of South Australia.
For African-Americans with high blood pressure, the combination of risk factors known as metabolic syndrome brings an increased risk of worsening kidney disease, reports a paper being presented at the American Society of Nephrology’s 39th Annual Meeting and Scientific Exposition in San Diego.
A standard tool for predicting cardiovascular disease (CVD) risk greatly underestimates the true rate of heart disease among patients receiving dialysis for end-stage renal disease (ESRD), reports a paper being presented at the American Society of Nephrology’s 39th Annual Meeting and Scientific Exposition in San Diego.
Results of a new analysis showed that patients who have heart disease and chronic kidney disease who took Lipitor? (atorvastatin calcium) Tablets (80 mg) reduced their risk of heart attack and stroke by 32 percent compared with patients taking the 10 mg dose of Lipitor. This analysis of a subset of patients from the five-year TNT (Treating to New Targets) study was designed and completed after the end of the trial. The data were presented here today at the Annual Scientific Sessions of the American Heart Association.
REGENERX BIOPHARMACEUTICALS, INC. (AMEX: RGN) reported today that a study published in the advanced online edition of the journal Nature supported and elaborated TB4’s significant effects in the damaged hearts of mice and highlighted its therapeutic potential for the treatment of heart attacks and heart failure in humans.
Virginia Commonwealth University researchers have developed a unique anti-sickling agent that may one day be effective in treating sickle cell disease, a painful and debilitating genetic blood disorder that affects approximately 80,000 Americans.